Articles
3 June 2009
Vol. 1 No. 9: 3rd International Conference on Thrombosis and Hemostasis Issues in Cancer, Bergamo, October 14-16, 2005
https://doi.org/10.4081/hmr.v1i9.323

Clinical trials with angiogenesis inhibitors

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
183
Views
187
Downloads

Authors

G Giaccone
support@pagepress.org
H van Cruijsen
Angiogenesis is essential for tumor growth and metastasis formation. Many agents have been developed to inhibit this process. Two major anti-angiogenic strategies have been so far mostly developed: the vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab and several tyrosine kinase inhibitors (TKI) to VEGF receptors. Bevacizumab is the first specific anti-angiogenic agent registered. This registration was based on the results of the phase III trial which compared first-line chemotherapy plus bevacizumab to chemotherapy alone in patients with metastatic colorectal cancer. Treatment with chemotherapy plus bevacizumab resulted in higher response rates (chemotherapy, 35%, chemotherapy plus bevacizumab, 45%) and longer median survival (chemotherapy, 15.6 months, chemotherapy plus bevacizumab, 20.3 months).1

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Clinical trials with angiogenesis inhibitors. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 1(9). https://doi.org/10.4081/hmr.v1i9.323